Firearm-owning veterans receptive to safety discussions in routine care
Jul 03, 2023
The findings are based on a survey encompassing six clinical contexts involving heightened risk for firearm injury.
Intranasal insulin may have pro-cognitive benefits
Jun 30, 2023
Improvement in global cognition was seen for patients with Alzheimer’s disease/mild cognitive impairment, but no effects were seen for healthy individuals or other patient populations.
Social isolation tied to wide variety of dementia risk factors
Feb 02, 2023
Social isolation may be a modifiable risk factor for preventing Alzheimer’s disease-related dementias, authors say.
Transcranial direct current stimulation beneficial in Alzheimer’s disease
Dec 07, 2023
Active tCDS improves cognitive functions in memory domain, including word recall, recall of test instructions and word recognition.
FDA gives full approval to Alzheimer’s disease drug Leqembi
Jul 06, 2023
Although Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds.
Diabetes plus tooth loss tied to worse cognition
Mar 24, 2023
Faster cognitive decline was seen for older adults with both conditions.
Neurological conditions ranked as leading cause of disability-adjusted life years globally
Mar 15, 2024
Between 1990 and 2021, there was an 18.2 percent increase in the global DALY counts attributed to those conditions
Number of teeth, periodontitis in older adults linked to hippocampal atrophy
Jul 06, 2023
A qualitative interaction was seen between the number of teeth present and the mean periodontal probing depth for symmetric percentage change in left hippocampus.
Home discharge down, mortality increased after ICU stay for dementia patients
Jul 17, 2023
Older adults with Alzheimer’s disease and related dementia have lower rates of home discharge and higher mortality.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.